Hideo Watanabe

St. Catherine University — United States

Immunology and Microbiology · Life Sciences

47h-index9.7kcitations728works0.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

interferon and immune responses(71), Epigenetics and DNA Methylation(49), RNA modifications and cancer(44), Lung Cancer Research Studies(42), Orthopedic Surgery and Rehabilitation(32)

Publications727 total

EGFR-mutant transformed small cell lung cancer harbors intratumoral heterogeneity targetable with MEK inhibitor combination therapy
JCI Insight·2026Open Access
681 TNG260, a novel small-molecule CoREST inhibitor, sensitizes STK11-mutant tumors to anti-PD-1 therapy
Regular and Young Investigator Award Abstracts·2025Open Access
Data from TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes <i>STK11</i>-Mutant Tumors to Anti–PD-1 Immunotherapy
2025Open Access
Supplemental Table 5 from TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes <i>STK11</i>-Mutant Tumors to Anti–PD-1 Immunotherapy
2025Open Access
Supplemental Figure 9 from TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes <i>STK11</i>-Mutant Tumors to Anti–PD-1 Immunotherapy
2025Open Access
Supplemental Table 3 from TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes <i>STK11</i>-Mutant Tumors to Anti–PD-1 Immunotherapy
2025Open Access
Supplemental Table 4 from TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes <i>STK11</i>-Mutant Tumors to Anti–PD-1 Immunotherapy
2025Open Access
Supplemental Figure 6 from TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes <i>STK11</i>-Mutant Tumors to Anti–PD-1 Immunotherapy
2025Open Access
Supplemental Figure 4 from TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes <i>STK11</i>-Mutant Tumors to Anti–PD-1 Immunotherapy
2025Open Access
Supplemental Figure 2 from TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes <i>STK11</i>-Mutant Tumors to Anti–PD-1 Immunotherapy
2025Open Access
Supplemental Figure 3 from TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes <i>STK11</i>-Mutant Tumors to Anti–PD-1 Immunotherapy
2025Open Access
Supplemental Figure 8 from TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes <i>STK11</i>-Mutant Tumors to Anti–PD-1 Immunotherapy
2025Open Access
Supplemental Figure 1 from TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes <i>STK11</i>-Mutant Tumors to Anti–PD-1 Immunotherapy
2025Open Access
Supplemental Table 6 from TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes <i>STK11</i>-Mutant Tumors to Anti–PD-1 Immunotherapy
2025Open Access
Supplemental Table 1 from TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes <i>STK11</i>-Mutant Tumors to Anti–PD-1 Immunotherapy
2025Open Access
Supplemental Table 2 from TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes <i>STK11</i>-Mutant Tumors to Anti–PD-1 Immunotherapy
2025Open Access
Supplemental Figure 5 from TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes <i>STK11</i>-Mutant Tumors to Anti–PD-1 Immunotherapy
2025Open Access
Supplemental Figure 7 from TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes <i>STK11</i>-Mutant Tumors to Anti–PD-1 Immunotherapy
2025Open Access
TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes <i>STK11</i> -Mutant Tumors to Anti–PD-1 Immunotherapy
Cancer Research·2025· 1 citedOpen Access
Induced lung epithelial-like cells derived by direct reprogramming rescue influenza virus-induced lung injury in mice
Biochemical and Biophysical Research Communications·2025· 1 citedOpen Access
page 1 of 37Next →

Frequent Co-authors

Yoshinao Nakagawa(15), Keiichi Tomishige(15), Matthew Meyerson(10), Kwok‐Kin Wong(9), Adam J. Bass(6), Peter S. Hammerman(6), Joshua M. Francis(5), Dalin Li(5), Masazumi Tamura(5), Shunsuke Kitajima(4), Tran C. Thai(4), David A. Barbie(4), Lei Wang(4), Kazu Okumura(4), Roel G.W. Verhaak(3), Pablo Tamayo(3), Anil K. Rustgi(3), Glenn Dranoff(3), Marco Campisi(3), Brandon Piel(3)